리소좀 축적 질환 치료제 시장 - 산업 규모, 점유율, 동향, 기회, 예측 : 치료법, 적응증, 최종 사용자, 지역별 경쟁(2021-2031년)

The Global Lysosomal Storage Diseases Therapeutics Market is projected to expand from USD 7.69 Billion in 2025 to USD 11.72 Billion by 2031, demonstrating a compound annual growth rate (CAGR) of 7.28%. These therapeutics involve specific medical interventions, such as enzyme replacement and substrate reduction therapies, designed to counteract the metabolic deficiencies stemming from lysosomal dysfunction. This market's expansion is primarily fueled by advancements in diagnostic capabilities, including newborn screening, and substantial public-private investments in research for orphan drugs. For instance, the National Institutes of Health allocated approximately $26 million in grants to the Rare Diseases Clinical Research Network in fiscal year 2025, underscoring the significant financial commitment to advance clinical studies for these conditions.

Despite this progress, a considerable hurdle impeding market growth is the exceptionally high cost associated with drug development and the subsequent pressure on pricing. Furthermore, the intricate regulatory environment, coupled with the difficulty of enrolling a sufficient number of participants for clinical trials due to small and geographically dispersed patient populations, creates significant obstacles that can delay the commercial introduction of new therapeutics.

Market Driver

Advancements in enzyme replacement and gene therapies are fundamentally transforming the Global Lysosomal Storage Diseases Therapeutics Market by shifting the clinical focus from mere palliative care to targeted disease modification. Innovative biologics are now engineered with improved cellular uptake mechanisms to more effectively address the underlying metabolic deficiencies of these complex conditions, thereby driving substantial commercial adoption. The commercial impact of these next-generation treatments is clearly reflected in the rapid growth of specialized portfolios; for example, Chiesi Group's Rare Diseases business unit achieved a 31.4% growth rate in the first half of 2025, highlighting the strong demand for its advanced therapeutic solutions.

Concurrently, supportive orphan drug policies and regulatory incentives play a crucial role in sustaining the high-risk development pipelines essential for these niche indications. Government programs offering market exclusivity and accelerated review pathways provide the necessary economic safeguards for biopharmaceutical companies to invest in treatments for limited patient populations. The effectiveness of this supportive framework is evident in regulatory outcomes, with 52% of novel drugs approved by the FDA in 2024 designated for rare diseases. This policy-driven environment directly translates into commercial sustainability, as demonstrated by Amicus Therapeutics reporting third-quarter 2025 total revenue of $169.1 million, confirming the ongoing financial viability of precision medicines in this sector.

Market Challenge

The prohibitive expense of drug development, alongside the inherent difficulties in recruiting an adequate number of participants for clinical trials, acts as a significant constraint on the Global Lysosomal Storage Diseases Therapeutics Market. These financial and logistical barriers escalate the attrition rate of new therapies, as companies face extended timelines and mounting costs to establish safety and efficacy in small, geographically dispersed patient groups. This high-risk environment often discourages sustained investment in all but the most commercially promising candidates, effectively narrowing the pipeline of potential treatments and decelerating the overall pace of market expansion.

The consequences of these hurdles are evident in the substantial gap between identified metabolic deficiencies and available medical interventions. According to the National Organization for Rare Disorders, over 95% of rare diseases still lacked an FDA-approved treatment in 2025. This statistic underscores the severity of the challenge: even with improved diagnostic capabilities, the economic burden of development often prevents the successful commercialization of therapies for the vast majority of these conditions, thereby limiting revenue growth and market maturity within the sector.

Market Trends

A distinct shift toward oral substrate reduction therapies is transforming the treatment landscape by offering a non-invasive alternative to lifelong intravenous infusions. This trend addresses the patient burden by inhibiting the accumulation of toxic substrates through convenient oral dosing, rather than relying exclusively on systemic enzyme replacement. The commercial appeal of this modality is robust; for example, Sanofi reported sales for its oral therapy Cerdelga reached 81 million Euros in Q3 2024, highlighting the sustained market demand for patient-centric delivery mechanisms, particularly in the Gaucher disease segment.

The strategic consolidation of orphan drug pipelines has emerged as a crucial mechanism for ensuring financial sustainability within the high-risk rare disease sector. Biopharmaceutical companies are increasingly assembling diverse portfolios of commercial-stage assets and late-stage candidates to mitigate the volatility associated with dependency on a single product. This diversified approach is yielding measurable stability, as demonstrated by Ultragenyx, which achieved total revenue of 139 million Dollars in Q3 2024, validating the economic strength of a consolidated platform focused on multiple rare metabolic indications.

Key Market Players

• Pfizer, Inc.
• Sanofi SA
• BioMarin Pharmaceutical Inc
• Actelion Ltd.
• Raptor Pharmaceutical Corp.
• Protalix Biotherapeutics Inc.
• Amicus Therapeutics, Inc.
• Quest Diagnostics Inc.
• Amicus Therapeutics Inc.
• Shire Plc

Report Scope

In this report, the Global Lysosomal Storage Diseases Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lysosomal Storage Diseases Therapeutics Market, By Treatment

• Enzyme Replacement Therapy
• Stem Cell Therapy
• Substrate Reduction Therapy
• others

Lysosomal Storage Diseases Therapeutics Market, By Indication

• Gaucher's Disease
• Fabry Disease
• Pompe's Disease
• Mucopolysaccharidosis
• others

Lysosomal Storage Diseases Therapeutics Market, By End User

• Hospitals
• Clinics

Lysosomal Storage Diseases Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lysosomal Storage Diseases Therapeutics Market.

Available Customizations:

Global Lysosomal Storage Diseases Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lysosomal Storage Diseases Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment (Enzyme Replacement Therapy, Stem Cell Therapy, Substrate Reduction Therapy, others)
  • 5.2.2. By Indication (Gaucher's Disease, Fabry Disease, Pompe's Disease, Mucopolysaccharidosis, others)
  • 5.2.3. By End User (Hospitals, Clinics)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Lysosomal Storage Diseases Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By Indication
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lysosomal Storage Diseases Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Lysosomal Storage Diseases Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Lysosomal Storage Diseases Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By End User

7. Europe Lysosomal Storage Diseases Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By Indication
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Lysosomal Storage Diseases Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By End User
  • 7.3.2. France Lysosomal Storage Diseases Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Lysosomal Storage Diseases Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Lysosomal Storage Diseases Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Lysosomal Storage Diseases Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By End User

8. Asia Pacific Lysosomal Storage Diseases Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By Indication
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Lysosomal Storage Diseases Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By End User
  • 8.3.2. India Lysosomal Storage Diseases Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Lysosomal Storage Diseases Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Lysosomal Storage Diseases Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Lysosomal Storage Diseases Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By End User

9. Middle East & Africa Lysosomal Storage Diseases Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By Indication
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Lysosomal Storage Diseases Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Lysosomal Storage Diseases Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Lysosomal Storage Diseases Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By End User

10. South America Lysosomal Storage Diseases Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment
  • 10.2.2. By Indication
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Lysosomal Storage Diseases Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Lysosomal Storage Diseases Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Lysosomal Storage Diseases Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Lysosomal Storage Diseases Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Sanofi SA
• 15.3. BioMarin Pharmaceutical Inc
• 15.4. Actelion Ltd.
• 15.5. Raptor Pharmaceutical Corp.
• 15.6. Protalix Biotherapeutics Inc.
• 15.7. Amicus Therapeutics, Inc.
• 15.8. Quest Diagnostics Inc.
• 15.9. Amicus Therapeutics Inc.
• 15.10. Shire Plc

16. Strategic Recommendations

17. About Us & Disclaimer